565 Shares in Humana Inc. (NYSE:HUM) Purchased by Generali Investments Management Co LLC

Generali Investments Management Co LLC acquired a new stake in Humana Inc. (NYSE:HUM) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 565 shares of the insurance provider’s stock, valued at approximately $143,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Pzena Investment Management LLC lifted its position in shares of Humana by 44.0% during the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock valued at $915,736,000 after buying an additional 1,103,132 shares in the last quarter. Boston Partners raised its position in Humana by 435.8% during the fourth quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock worth $279,236,000 after acquiring an additional 893,637 shares during the period. FMR LLC lifted its holdings in Humana by 23.4% during the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after purchasing an additional 643,291 shares in the last quarter. Retirement Systems of Alabama grew its position in shares of Humana by 735.9% in the fourth quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider’s stock valued at $55,563,000 after purchasing an additional 192,801 shares during the period. Finally, Worldquant Millennium Advisors LLC purchased a new stake in shares of Humana during the third quarter worth about $50,102,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

HUM has been the topic of a number of research reports. Morgan Stanley decreased their price target on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. JPMorgan Chase & Co. reduced their target price on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a report on Tuesday, February 18th. Barclays lifted their price target on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 price target on shares of Humana in a research report on Wednesday, February 12th. Finally, Piper Sandler raised their price objective on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a report on Wednesday, January 15th. Nineteen equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $285.68.

Insider Transactions at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.37% of the company’s stock.

Humana Price Performance

Shares of HUM stock opened at $267.01 on Thursday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The company has a market capitalization of $32.23 billion, a PE ratio of 26.84, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The firm’s 50-day moving average is $271.43 and its two-hundred day moving average is $278.21. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46.

Humana (NYSE:HUM) last released its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.33%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.